A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial

CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II trial designed to determine whether treatment with autologous bone marrow‐derived mesenchymal stromal cells (MSCs) and c‐kit positive cardiac cells (CPCs), given alone or in combination, is feasible, safe, and beneficial in patients with heart failure (HF) caused by ischaemic cardiomyopathy.

[1]  Akshay S. Desai,et al.  Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial , 2016, The Lancet.

[2]  Amit N. Patel,et al.  Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy , 2014, Circulation research.

[3]  R. Bolli,et al.  New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types. , 2018, Circulation research.

[4]  Doris A Taylor,et al.  Global position paper on cardiovascular regenerative medicine , 2017, European heart journal.

[5]  E. Marbán,et al.  c-kit+ Cells Minimally Contribute Cardiomyocytes to the Heart , 2014, Nature.

[6]  Roberto Bolli,et al.  Cell Therapy for Heart Failure: A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions , 2013, Circulation research.

[7]  Doris A Taylor,et al.  Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. , 2011, JAMA.

[8]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[9]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[10]  R. Bolli,et al.  After the Storm: An Objective Appraisal of the Efficacy of c-kit+ Cardiac Progenitor Cells in Preclinical Models of Heart Disease. , 2020, Canadian journal of physiology and pharmacology.

[11]  Zuoren Yu,et al.  C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner. , 2017, Journal of cardiac failure.

[12]  R. Bolli,et al.  Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy. , 2016, Circulation research.

[13]  Joshua M Hare,et al.  Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. , 2006, Journal of the American College of Cardiology.

[14]  B. Greenberg,et al.  Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure , 2019, Circulation research.

[15]  F. Fernández‐Avilés,et al.  The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016 , 2017, European heart journal.

[16]  L. Amado,et al.  Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. , 2008, American journal of physiology. Heart and circulatory physiology.

[17]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Journal of the American College of Cardiology.

[18]  Yi Zheng,et al.  A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. , 2015, Circulation research.

[19]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[20]  Darcy L. DiFede,et al.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. , 2014, JAMA.

[21]  Joshua M Hare,et al.  Enhanced Effect of Combining Human Cardiac Stem Cells and Bone Marrow Mesenchymal Stem Cells to Reduce Infarct Size and to Restore Cardiac Function After Myocardial Infarction , 2013, Circulation.

[22]  D. Gordon,et al.  Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). , 2013, Circulation.

[23]  J. Kovacic,et al.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.

[24]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association , 2020, Circulation.

[25]  Peter A. Altman,et al.  Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy: Functional Recovery and Reverse Remodeling , 2011, Circulation research.

[26]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[27]  Ftlo Bonin-Cecelia,et al.  Phase II: , 2020, The Power of Accountability.

[28]  Doris A Taylor,et al.  Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. , 2012, JAMA.

[29]  R. Bolli,et al.  c-kit+ Cardiac Stem Cells Alleviate Post-Myocardial Infarction Left Ventricular Dysfunction Despite Poor Engraftment and Negligible Retention in the Recipient Heart , 2014, PloS one.

[30]  P. Pattany,et al.  Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation , 2010, Circulation research.

[31]  Left Ventricular End-Diastolic Volume Index , 2021, Encyclopedia of Gerontology and Population Aging.

[32]  S. Kozerke,et al.  Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results. , 2016, Circulation research.

[33]  J. Kastrup,et al.  Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). , 2015, European heart journal.

[34]  P. Pattany,et al.  Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[35]  P. Pattany,et al.  Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity , 2009, Proceedings of the National Academy of Sciences.

[36]  R. Bolli,et al.  Long-Term Outcome of Administration of c-kit(POS) Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do not Become Cardiomyocytes, but Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at Least One Year. , 2016, Circulation research.

[37]  Gillian L. Currie,et al.  Cardiac Stem Cell Treatment in Myocardial InfarctionNovelty and Significance , 2016 .

[38]  Doris A Taylor,et al.  Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure) , 2018, Circulation research.

[39]  M. Zviman,et al.  Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. , 2009, European heart journal.

[40]  Joshua M Hare,et al.  Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Bolli,et al.  Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions , 2018, Circulation research.

[42]  C. McCarthy,et al.  Inflammation in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[43]  James E. Tcheng,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials , 2018, Circulation.

[44]  Katherine C. Wu,et al.  Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Sur , 2014, Circulation research.

[45]  R. Bolli,et al.  "String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. , 2015, Circulation research.

[46]  J. Hare,et al.  Use of mesenchymal stem cells for therapy of cardiac disease. , 2015, Circulation research.